Two Years Of Clinical Experience Outcome Review On Radium223 Therapy In Bone Metastatic Castrate-resistent Prostate Cancer

被引：0
|
作者：
Pena, H. [1 ]
Cantinho, G. [1 ]
Graca, A. [1 ]
Fernandes, A. [1 ]
Fernandes, I. [2 ]
Costa, L. [2 ]
机构：
[1] Univ Lisbon, Fac Med, Inst Med Nucl, Lisbon, Portugal
[2] Ctr Hosp Lisboa Norte, S Oncol, Lisbon, Portugal
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0681
引用
收藏
页码：S571 / S571
页数：1
相关论文
共 50 条
  • [1] Seven Years of Clinical Experience Outcome Review on Radium 223 Therapy In Bone Metastatic Castrate-resistant Prostate Cancer (mCRPC)
    Cantinho-Lopes, M.
    Pena, H.
    Filipe, P.
    Mansinho, A.
    Fernandes, I.
    Costa, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S400 - S400
  • [2] Radium-223 therapy for metastatic castrate-resistant prostate cancer
    Lehman, Ashley
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [3] Radium-223 therapy for metastatic castrate-resistant prostate cancer
    Lehman, Ashley
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [4] Radium223 in castration resistant prostate cancer with bone metastases: preliminary clinical results
    Rambaldi, G. Zanirato
    Ferioli, M.
    Montini, G. C.
    Di Tullio, P. G.
    Pettinato, C.
    Di Bartolomeo, M.
    Panni, V.
    Ardizzoni, A.
    Marengo, M.
    Fanti, S.
    Frezza, G.
    Morganti, A. G.
    Monari, F.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S667 - S667
  • [5] Three years' clinical practice of Radium-223 therapy in patients with symptomatic bone metastases from metastatic castrate-resistant prostate cancer: a single centre experience
    Gazzilli, M.
    Durmo, R.
    Albano, D.
    Cerudelli, E.
    Panarotto, M.
    Cossalter, E.
    Bertagna, F.
    Giubbini, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S628 - S628
  • [6] Radium 223 Therapy in Symptomatic Metastatic Castrate Resistant Prostate Cancer - Newcastle Experience: a Quality of Life Issue
    Jiang, X. Y.
    Atkinson, S.
    Frew, J.
    McMenemin, R.
    Leaning, D.
    Pedley, I.
    CLINICAL ONCOLOGY, 2018, 30 (03) : 194 - 194
  • [7] Three years' clinical practice of Radium-223 therapy in patients with symptomatic bone metastases from metastatic castrate-resistant prostate cancer: a single-centre experience
    Gazzilli, Maria
    Durmo, Rexhep
    Cossalter, Erika
    Cerudelli, Elisabetta
    Panarotto, Maria Beatrice
    Albano, Domenico
    Bertagna, Francesco
    Giubbini, Raffaele
    NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (04) : 300 - 307
  • [8] Radium-223 for Metastatic Castrate-Resistant Prostate Cancer
    Sindhu, Kunal K.
    Nehlsen, Anthony D.
    Stock, Richard G.
    PRACTICAL RADIATION ONCOLOGY, 2022, 12 (04) : 312 - 316
  • [9] Single Center Clinical Experience With Radium-223 Dichloride In Patients With Metastatic Castrate-resistant Prostate Cancer
    Tiskevicius, S.
    Vidrinskaite, A.
    Stalnionis, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S572 - S572
  • [10] Clinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and bone metastases
    Exadaktylou, P.
    Paschali, A.
    Panagiotidis, E.
    Papadopoulos, N.
    Kalathas, T.
    Giannoula, E.
    Kotzasarlidou, M.
    Chatzipavlidou, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S569 - S570
12345